Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments

Treatments used for managing atopic dermatitis (AD) may have adverse ocular effects that permanently affect vision. The objective of this review is to raise awareness among dermatologists regarding the potential ocular adverse effects of various AD therapies, including corticosteroids, calcineurin i...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2019-12, Vol.20 (6), p.807-815
Main Authors: Beck, Kristen M., Seitzman, Gerami D., Yang, Eric J., Sanchez, Isabelle M., Liao, Wilson
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - adverse effects
Antibodies, Monoclonal, Humanized - adverse effects
Calcineurin Inhibitors - adverse effects
Cataracts
Dermatitis
Dermatitis, Atopic - therapy
Dermatologic Agents - adverse effects
Dermatology
Eczema
Eye Diseases - epidemiology
Eye Diseases - etiology
Eye Diseases - prevention & control
Glaucoma
Humans
Intraocular Pressure - drug effects
Medicine
Medicine & Public Health
Monoclonal antibodies
Patients
Pharmacology/Toxicology
Pharmacotherapy
Phototherapy - adverse effects
Phototherapy - methods
Review Article
Risk factors
Visual impairment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatments used for managing atopic dermatitis (AD) may have adverse ocular effects that permanently affect vision. The objective of this review is to raise awareness among dermatologists regarding the potential ocular adverse effects of various AD therapies, including corticosteroids, calcineurin inhibitors, an interleukin-4 receptor α (IL-4Rα) antagonist, and phototherapy. Pertinent potential short- and long-term risks of these therapies include elevations in intraocular pressure from use of topical corticosteroids and conjunctivitis from use of dupilumab. Since some of these adverse effects may not exhibit symptomatology until permanent vision impairment occurs, it is important for dermatologists to understand these risks and proactively ensure their patients are receiving appropriate measures to prevent them.
ISSN:1175-0561
1179-1888
DOI:10.1007/s40257-019-00465-3